CoChat

Residual macrovascular risk in 2013: what have we learned?

Open access
for the Residual Risk Reduction Initiative (R3i), Fruchart, Jean-Charles, Davignon, Jean, Hermans, Michel P, Al-Rubeaan, Khalid, Amarenco, Pierre, Assmann, Gerd, Barter, Philip, Betteridge, John, Bruckert, Eric, Cuevas, Ada, Farnier, Michel, Ferrannini, Ele, Fioretto, Paola, Genest, Jacques, Ginsberg, Henry N, Gotto, Antonio M, Hu, Dayi, Kadowaki, Takashi, Kodama, Tatsuhiko, Krempf, Michel, Matsuzawa, Yuji, Núñez-Cortés, Jesús Millán, Monfil, Carlos Calvo, Ogawa, Hisao, Plutzky, Jorge, Rader, Daniel J, Sadikot, Shaukat, Santos, Raul D, Shlyakhto, Evgeny, Sritara, Piyamitr, Sy, Rody, Tall, Alan, Tan, Chee Eng, Tokgözoğlu, Lale, Toth, Peter P, Valensi, Paul, Wanner, Christoph, Zambon, Alberto, Zhu, Junren, Zimmet, Paul · 2014 · Cardiovascular Diabetology
Cited by 172

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

Cardiovascular disease poses a major challenge for the 21st century, exacerbated by the pandemics of obesity, metabolic syndrome and type 2 diabetes. While best standards of care, including high-dose statins, can ameliorate the risk of vascular complications, patients remain at high risk of cardiovascular events. The Residual Risk Reduction Initiative (R3i) has previously highlighted atherogenic dyslipidaemia, defined as the imbalance between proatherogenic triglyceride-rich apolipoprotein B-containing-lipoproteins and antiatherogenic apolipoprotein A-I-lipoproteins (as in high-density lipoprotein, HDL), as an important modifiable contributor to lipid-related residual cardiovascular risk, especially in insulin-resistant conditions. As part of its mission to improve awareness and clinical management of atherogenic dyslipidaemia, the R3i has identified three key priorities for action: i) to improve recognition of atherogenic dyslipidaemia in patients at high cardiometabolic risk with or without diabetes; ii) to improve implementation and adherence to guideline-based therapies; and iii) to improve therapeutic strategies for managing atherogenic dyslipidaemia. The R3i believes that monitoring of non-HDL cholesterol provides a simple, practical tool for treatment decisions regarding the management of lipid-related residual cardiovascular risk. Addition of a fibrate, niacin (North and South America), omega-3 fatty acids or ezetimibe are all options for combination with a statin to further reduce non-HDL cholesterol, although lacking in hard evidence for cardiovascular outcome benefits. Several emerging treatments may offer promise. These include the next generation peroxisome proliferator-activated receptorα agonists, cholesteryl ester transfer protein inhibitors and monoclonal antibody therapy targeting proprotein convertase subtilisin/kexin type 9. However, long-term outcomes and safety data are clearly needed. In conclusion, the R3i believes that ongoing trials with these novel treatments may help to define the optimal management of atherogenic dyslipidaemia to reduce the clinical and socioeconomic burden of residual cardiovascular risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1475-2840-13-26

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 172

Metadata

Authors
(R3i), F. T. R. R. R. I., Fruchart, J.-C., Davignon, J., Hermans, M. P., Al-Rubeaan, K., Amarenco, P., Assmann, G., Barter, P., Betteridge, J., Bruckert, E., Cuevas, A., Farnier, M., Ferrannini, E., Fioretto, P., Genest, J., Ginsberg, H. N., Gotto, A. M., Hu, D., Kadowaki, T., Kodama, T., Krempf, M., Matsuzawa, Y., Núñez-Cortés, J. M., Monfil, C. C., Ogawa, H., Plutzky, J., Rader, D. J., Sadikot, S., Santos, R. D., Shlyakhto, E., Sritara, P., Sy, R., Tall, A., Tan, C. E., Tokgözoğlu, L., Toth, P. P., Valensi, P., Wanner, C., Zambon, A., Zhu, J., & Zimmet, P.
Venue
Cardiovascular Diabetology
Published
2014-01-24
Volume
13
Issue
1
Pages
26-26
ISSN
1475-2840 (ISSN-L)
OpenAlex
W2132196134
Cited by
172
References
53
FWCI
23.30
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Residual macrovascular risk in 2013: what have we learned? https://app.cochat.ai/papers/10.1186/1475-2840-13-26
The paper
(R3i), F. T. R. R. R. I., Fruchart, J.-C., Davignon, J., Hermans, M. P., Al-Rubeaan, K., Amarenco, P., Assmann, G., Barter, P., Betteridge, J., Bruckert, E., Cuevas, A., Farnier, M., Ferrannini, E., Fioretto, P., Genest, J., Ginsberg, H. N., Gotto, A. M., Hu, D., Kadowaki, T., . . . Zimmet, P. (2014). Residual macrovascular risk in 2013: what have we learned? Cardiovascular Diabetology. https://doi.org/10.1186/1475-2840-13-26

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.